Thomas Graf, MD, chief medical officer and vice president, Horizon Blue Cross Blue Shield of New Jersey, discusses evolving care bundle payments to better accommodate cancer patients.
Thomas Graf, MD, chief medical officer and vice president, Horizon Blue Cross Blue Shield of New Jersey, discusses evolving care bundle payments to better accommodate cancer patients.
Transcript
How can the patient-centered medical home model provide consistent high-quality care for patients, and how will novel therapies affect it?
In some sense, this isn’t a PCMH model. These patients aren’t being addressed by primary care doctors or family physicians. They are generally being treated by oncologists. One approach is the oncology medical home model, which is basically medical home for active cancer treatment patients, and that’s one approach to this, and CMS has found a way to incorporate new very expensive drug treatments into their model, which is helpful. I think the other approach that might be more amenable to this novel therapy issue are episodes of care bundled payment where we really focus on bundles and the delivery of care for a defined period. The challenge there is unlike heart failure or COPD or joint replacement, the variation from patient to patient, member to member, is significant.
Cancer, specifically lung cancer, is not a lung cancer is not a lung cancer. So, being able to precisely define the patient and understand the clinical differences that they have and create what we call precision models, maybe phenotypically driven, maybe more likely genotypically driven, or most likely a combination of both, will be critical. Instead of having one lung cancer bundle there might be a dozen depending on the type of treatments the patients need. Then, the patients that qualify or need or would get benefit from those high cost drugs could be included in that. For those that don’t, they would have a different price point per episode. That, I think is the beginning of the way forward. We have to wait and see how that turns out.
New TROPiCS-02 Data Back Sacituzumab Govitecan for Older Patients With Breast Cancer
December 9th 2023This phase 3 study investigated sacituzumab govitecan, a Trop-2–directed antibody-drug conjugate, vs treatment of physician’s choice in pretreated patients who have endocrine-resistant hormone receptor–positive/HER2-negative breast cancer, the most common form of breast cancer.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
California Aims for Equity by Redefining Cancer Care
December 8th 2023Authors highlight key aspects of the California Cancer Care Equity Act, including its focus on Medi-Cal beneficiaries, the requirement for managed care plans to contract with specialized cancer centers, and the definition of complex cancers.
Read More
Research Reveals the Role of Structural Racism in Lung Cancer Risk
December 7th 2023Spanning 22 studies, the analysis illuminated housing disparities, occupational hazards, unequal health care access, economic inequality, and discriminatory industry practices and how they collectively contribute to heightened lung cancer risks.
Read More
Refining Precision Prevention for Benign Breast Disease
December 7th 2023Many questions remain surrounding accurately classifying the risk of developing invasive breast cancer associated with the benign breast disease diagnoses of nonproliferative lesions and proliferative changes without atypia.
Read More